Vanda Pharmaceuticals Inc. (VNDA)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 3
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, so this strategy cannot admit a bullish entry despite the short-term repair bounce.
Company overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for unmet medical needs. It offers HETLIOZ for non-24-hour sleep-wake disorders and Fanapt for schizophrenia. The company is expanding its pipeline to include treatments for various conditions such as jet lag disorder and bipolar disorder.
Fundamental
weakVanda Pharmaceuticals faces significant cash burn and competitive pressures, making it a high-risk turnaround candidate.
Commercial-stage biotech with very high gross margins but currently deep losses and heavy cash burn. SEC filings show no going-concern warning and modest debt, yet liquidity has been shrinking as operating cash outflows accelerated. The stock is inexpensive on EV/Sales, but negative free cash flow and competitive pressure (notably generic impact on HETLIOZ) make it more of a high-risk turnaround/watchlist than a clean short-term fundamental buy.
Sentiment
weakRecent sentiment is weak due to negative earnings and declining HETLIOZ sales.
Near-term narrative is dominated by the Aug 5 Q2 earnings update (announced) that was broadly received as a miss (wider loss and revenue lagging expectations, driven by Hetlioz sales decline), and last ~14d media sentiment (polarity_score ≈ -0.17) has deteriorated from a bullish 30–90d baseline (≈ +0.43). No regulator-confirmed investigations surfaced, but a moderate red-flag cap applies because sentiment flipped sharply post-print and the only counter-signal is low-confidence, rumor-driven buzz.
Technical
fairThe stock shows a short-term repair bounce but remains in a broader downtrend.
Short-term rebound reclaimed the SMA20 and EMA9 with a positive MACD histogram, but VNDA is still below the EMA21, SMA50 and SMA200 while MACD remains below zero, so the broader trend is not yet bullish.
You’re looking at 2026-08-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.